Literature DB >> 15086655

Clinically relevant levels of depressive symptoms in community-dwelling middle-aged African Americans.

Douglas K Miller1, Theodore K Malmstrom, Seema Joshi, Elena M Andresen, John E Morley, Fredric D Wolinsky.   

Abstract

OBJECTIVES: To identify the prevalence of and potentially modifiable risk factors for clinically relevant levels of depressive symptoms in a population-based sample of community-dwelling African Americans and the prevalence of treatment by prescription and alternative medications.
DESIGN: Cross-sectional survey, 2000-01.
SETTING: Community-based. PARTICIPANTS: Nine hundred ninety-eight noninstitutionalized African Americans in St. Louis, Missouri, born between 1936 and 1950. MEASUREMENTS: Depressive symptoms were measured using the 11-item Center for Epidemiologic Studies Depression scale (CES-D). Clinically relevant levels of depressive symptoms were defined as nine or more (equivalent to >/=16 on the 20-item CES-D). A comprehensive set of risk factors was considered that included three demographic variables, eight socioeconomic-access measures, four environmental factors, seven measures of functional status, 15 biomedical markers, one service utilization indicator, and three psychosocial measures. All analyses were weighted to the represented population. Treatment with an antidepressant was determined by examining subjects' medications compiled in their homes.
RESULTS: Two hundred ten subjects (21.1%) had clinically relevant levels of depressive symptoms. Several multivariate logistic regression approaches were used for model building, which identified a consistent set of nine predictive factors: female sex (odds ratio adjusted (AOR) for all factors in the final model=1.52; 95% confidence interval (CI)=1.01-2.27), lower objective income (AOR=1.62, 95% CI=1.08-2.43), perceived income inadequacy (AOR=2.33, 95% CI=1.49-3.65), lower assessment of home environment (AOR=1.07 per scale point, 95% CI=1.01-1.12), limitations in visual acuity (AOR=1.12 per scale point, 95% CI=1.04-1.21), being severely underweight (AOR=2.52, 95% CI=1.02-6.20), being obese (AOR=1.72, 95% CI=1.16-2.54), being hospitalized in the previous year (AOR=2.25, 95% CI=1.45-3.49), and lower social support (AOR=1.20 per scale point, 95% CI=1.16-1.26). Of these, social support was the most important (adjusted standardized odds ratio =2.41). Forty-one (19.5%) of the subjects with clinically relevant levels of depressive symptoms were taking prescription antidepressants.
CONCLUSION: The prevalence of clinically relevant levels of depressive symptoms in middle-aged African Americans was greater than that for the general U.S. population. Community-based health programs that screen for depression and refer individuals to clinical care sites with appropriately designed systems of care for depression management should be developed. For optimal effect, these programs should concentrate their efforts in socioeconomically disadvantaged areas and address socioeconomic factors such as income inadequacy and social support in addition to the biomedical risk factors. Given the pervasive adverse effects of depression, such interventions have the potential for significantly enhancing the health of African Americans in their later years and reducing current health disparities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086655     DOI: 10.1111/j.1532-5415.2004.52211.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  51 in total

1.  Identification of and beliefs about depressive symptoms and preferred treatment approaches among community-living older African Americans.

Authors:  Laura N Gitlin; Nancy L Chernett; Marie P Dennis; Walter W Hauck
Journal:  Am J Geriatr Psychiatry       Date:  2012-11       Impact factor: 4.105

2.  Personality, Negative Interactions, and Mental Health.

Authors:  Karen D Lincoln
Journal:  Soc Serv Rev       Date:  2008-06-01

3.  Financial Strain, Negative Interactions, and Mastery: Pathways to Mental Health Among Older African Americans.

Authors:  Karen D Lincoln
Journal:  J Black Psychol       Date:  2007-11

4.  A home-based intervention to reduce depressive symptoms and improve quality of life in older African Americans: a randomized trial.

Authors:  Laura N Gitlin; Lynn Fields Harris; Megan C McCoy; Nancy L Chernett; Laura T Pizzi; Eric Jutkowitz; Edward Hess; Walter W Hauck
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

5.  Depressive symptoms and risk of uterine leiomyomata.

Authors:  Lauren A Wise; Se Li; Julie R Palmer; Lynn Rosenberg
Journal:  Am J Obstet Gynecol       Date:  2014-12-13       Impact factor: 8.661

6.  Prevalence and treatment of diagnosed depression among elderly nursing home residents in Ohio.

Authors:  Carrie A Levin; Wenhui Wei; Ayse Akincigil; Judith A Lucas; Scott Bilder; Stephen Crystal
Journal:  J Am Med Dir Assoc       Date:  2007-10-22       Impact factor: 4.669

Review 7.  Late-life depression in older African Americans: a comprehensive review of epidemiological and clinical data.

Authors:  Yolonda R Pickett; Kisha N Bazelais; Martha L Bruce
Journal:  Int J Geriatr Psychiatry       Date:  2012-12-07       Impact factor: 3.485

8.  Patient ethnicity and perceptions of families and friends regarding depression treatment.

Authors:  Hillary Bogner; Larissa N Dobransky; Marsha N Wittink
Journal:  Ethn Health       Date:  2008-11-01       Impact factor: 2.772

9.  Predictors of change in grip strength over 3 years in the African American health project.

Authors:  Douglas K Miller; Theodore K Malmstrom; J Philip Miller; Elena M Andresen; Mario Schootman; Fredric D Wolinsky
Journal:  J Aging Health       Date:  2010-01-05

10.  Neighborhood conditions, diabetes, and risk of lower-body functional limitations among middle-aged African Americans: a cohort study.

Authors:  Mario Schootman; Elena M Andresen; Fredric D Wolinsky; J Philip Miller; Yan Yan; Douglas K Miller
Journal:  BMC Public Health       Date:  2010-05-27       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.